TY - JOUR
T1 - Functionalized carbon nanotubes for potential medicinal applications
AU - Zhang, Yi
AU - Bai, Yuhong
AU - Yan, Bing
N1 - Funding Information:
This work was supported by the National Basic Research Program of China (973 Program 2010CB933504), National Science Foundation of China (90913006), National Cancer Institute (P30CA021765) in the USA, the American Lebanese Syrian Associated Charities (ALSAC) and St. Jude Children's Research Hospital . Yi Zhang graduated in 2001 from the Hubei Polytechnic University with BS in Biological Engineering. He completed his Masters Degree at the School of Life Science, Shandong University in 2004. Since 2007, he has been a Ph.D. student in medicinal chemistry under the supervision of Prof. Bing Yan at Shandong University. His primary interests are in two areas, the first one is focused on the potential toxicology of carbon nanotubes, and the other is in the biomedical applications of carbon nanotubes and other nano-scale materials. Yuhong Bai , born in 1983, received his B.S. in biology in 2005 from Shandong University in Jinan, China. Since 2006 he has been a graduate student pursuing M.S. and Ph.D. in drug toxicology under the supervision of Prof. Bing Yan at Shandong University. His research is on the reproductive toxicity of nanomaterials. Bing Yan got his Ph.D. from Columbia University with Koji Nakanishi in 1990. He was a postdoctoral fellow at University of Cambridge from 1990 to 1991, and at University of Texas Medical School in Houston from 1991 to 1993. From 1993 to 2005, he worked at Novartis, Discovery Partners International, and Bristol-Myers Squibb. Now he is a faculty member at Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital in Memphis, Tennessee and professor at Shandong University. He has published or edited 10 books and more than 120 peer reviewed papers. He is the editor of book series ‘Critical Reviews in Combinatorial Chemistry’ published by Francis & Taylor Group. He also serves as associate editor for ‘Journal of Combinatorial Chemistry’ published by American Chemical Society.
PY - 2010/6
Y1 - 2010/6
N2 - Functionalized carbon nanotubes display unique properties that enable a variety of medicinal applications, including the diagnosis and treatment of cancer, infectious diseases and central nervous system disorders, and applications in tissue engineering. These potential applications are particularly encouraged by their ability to penetrate biological membranes and relatively low toxicity. High aspect ratio, unique optical property and the likeness as small molecule make carbon nanotubes an unusual allotrope of element carbon. After functionalization, carbon nanotubes display potentials for a variety of medicinal applications, including the diagnosis and treatment of cancer, infectious diseases and central nervous system disorders, and applications in tissue engineering. These potential applications are particularly encouraged by their ability to penetrate biological membranes and relatively low toxicity.
AB - Functionalized carbon nanotubes display unique properties that enable a variety of medicinal applications, including the diagnosis and treatment of cancer, infectious diseases and central nervous system disorders, and applications in tissue engineering. These potential applications are particularly encouraged by their ability to penetrate biological membranes and relatively low toxicity. High aspect ratio, unique optical property and the likeness as small molecule make carbon nanotubes an unusual allotrope of element carbon. After functionalization, carbon nanotubes display potentials for a variety of medicinal applications, including the diagnosis and treatment of cancer, infectious diseases and central nervous system disorders, and applications in tissue engineering. These potential applications are particularly encouraged by their ability to penetrate biological membranes and relatively low toxicity.
UR - http://www.scopus.com/inward/record.url?scp=77954817236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954817236&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2010.04.005
DO - 10.1016/j.drudis.2010.04.005
M3 - Review article
C2 - 20451656
AN - SCOPUS:77954817236
SN - 1359-6446
VL - 15
SP - 428
EP - 435
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 11-12
ER -